Viatris Inc

+0.07 (+0.44%)

Biocon Biologics Gets Deferred FDA Action On License Application For Avastin Biosimilar

Published: 12/25/2020 08:31 GMT
Viatris Inc (VTRS) - FDA Tells Biocon Biologics of Deferred Action on License Application for Myl-1402o, Proposed Biosimilar to Avastin.
FDA Says Inspection of Plant Required to Complete Application.
FDA Unable to Conduct Inspection Currently Due to Covid-19 Restrictions.
FDA Made No Other Observations Related to Application.